Regenerative Medicine & Cell Therapy Development

Developing Next-Generation Regenerative Medicines

Nordic Cell Therapy Ventures is our R&D arm dedicated to the development of innovative cell-based therapies aimed at addressing serious diseases with limited treatment options.Our programs focus on regenerative medicine and the therapeutic potential of stem cell–derived products. By combining scientific insight, translational expertise, and strategic development approaches, we aim to advance new therapies toward clinical application.Through internal programs and collaborations with leading research groups and industry partners, we work to transform advances in cell biology into meaningful therapeutic solutions.
‍

‍Advancing the Next Generation of Cell Therapies

‍In parallel with our consulting and analytic activities, Nordic Cell Therapy Ventures is actively developing proprietary regenerative medicine programs.
Our internal R&D efforts build on years of experience in pluripotent stem cell biology, differentiation, and translational development, with a focus on diseases where cell replacement can bring meaningful patient benefit.While details of our ongoing projects remain confidential for now, our team is pursuing first-in-class cell-based approaches that address areas of high unmet medical need. Each program integrates scientific innovation with pragmatic development planning from process design to non-clinical evaluation and regulatory strategy.Our R&D group currently includes a dedicated team of scientists and project leaders with expertise spanning discovery biology, CMC, and translational development. Together, we aim to transform advanced stem-cell concepts into future therapeutic solutions.
‍

‍Science in motion — advancing tomorrow’s therapies, today

Limbal Stem Cell Deficiency (LSCD) Program

LSCD is a rare but devastating condition in which the limbal epithelial stem cells, responsible for maintaining and regenerating the corneal surface, are lost or dysfunctional. Patients experience chronic pain, recurrent epithelial breakdown, inflammation, and progressive loss of vision. Severe cases, including those affecting both eyes, often leave individuals with no effective long-term treatment options.Advances in regenerative medicine are opening new possibilities for restoring the integrity and function of the ocular surface. At the Nordic Cell Therapy Group, we are committed to translating these possibilities into meaningful therapeutic solutions.

Limbal Stem Cell Deficiency (LSCD) Program

Our Approach
‍
‍Nordic Cell Therapy R&D is developing a next-generation limbal stem cell–based therapy designed to restore corneal epithelial regeneration in patients with LSCD. Our approach builds on three pillars:
‍
‍1. State-of-the-art stem cell biology.
2. Translational expertise across preclinical research, CMC, and regulatory strategy.
3. A rigorous development framework focusing on safety, reproducibility, and scalability.
‍
‍Our LSCD program is currently in pre-clinical development, where we are establishing the foundational scientific work needed to advance toward future clinical translation.
‍

‍Program Status
‍
‍The LSCD program has reached a stage of pre-clinical maturity, supported by ongoing in vitro studies and early exploratory in vivo activities. Future work will focus on:
‍
‍¤ Optimizing the cell therapy product and process.
¤ Advancing translational models.
¤ Preparing for CMC and regulatory readiness.
¤ Building the partnerships required for clinical progression.
‍
‍We pursue this development with a strong commitment to scientific integrity, patient needs, and responsible innovation.
‍

‍Partner With Us
‍
‍Nordic Cell Therapy R&D welcomes collaboration with clinicians, research groups, foundations, and investors who share our vision of enabling new therapeutic options for LSCD.
‍
To explore partnership, scientific collaboration, or support for this program, please contact us.
‍

OUR TEAM

Dmitry Penkov

SENIOR SCIENTIST | IPSC PLATFORM & FUNCTIONAL GENOMICS

Dmitry Penkov is a Senior Scientist with more than 15 years of experience developing human iPSC-based platforms for translational cell therapy. His expertise includes iPSC differentiation, functional genomics, CRISPR-based target validation, and cell-based assay development, including potency and release testing.
‍

Signe Frazier

SCIENTIST | NEURAL STEM CELLS & EXTRACELLULAR VESICLES

Signe Frazier is a Scientist with expertise in neural stem cells, neuronal differentiation, and extracellular vesicles for neurodegenerative disorders. Her recent PhD work at Novo Nordisk and the University of Copenhagen focused on neural stem cell–derived exosomes and their therapeutic potential in neurodegeneration.
‍

They collaborate with Nordic Cell Therapy Group on a project basis as independent professionals, contributing voluntarily to our early R&D programs.

Join us in advancing these programs

Be Part of the Future of Cell TherapyAt Nordic Cell Therapy Group, we are advancing innovative research programs that aim to make cell-based therapies a reality for patients.While our consultancy drives progress across the field, our internal R&D arm focuses on developing next-generation regenerative treatments in areas of high unmet medical need.If you share our vision and wish to support one of our research programs, please reach out to discuss how your contribution can make a measurable impact.Together, we can help shape the future of cell therapy. One breakthrough at a time.
‍
To explore partnership, scientific collaboration, or support for this program, please contact us.